WO2002043757A3 - Arzneimittel zur vermeidung oder behandlung von durch humanen papillomavirus-typ 18-hervorgerufenem tumor - Google Patents

Arzneimittel zur vermeidung oder behandlung von durch humanen papillomavirus-typ 18-hervorgerufenem tumor Download PDF

Info

Publication number
WO2002043757A3
WO2002043757A3 PCT/EP2001/014038 EP0114038W WO0243757A3 WO 2002043757 A3 WO2002043757 A3 WO 2002043757A3 EP 0114038 W EP0114038 W EP 0114038W WO 0243757 A3 WO0243757 A3 WO 0243757A3
Authority
WO
WIPO (PCT)
Prior art keywords
medicament
preventing
virus type
papilloma virus
human papilloma
Prior art date
Application number
PCT/EP2001/014038
Other languages
English (en)
French (fr)
Other versions
WO2002043757A2 (de
Inventor
Rainer Mueller
John Nieland
Josef Gabelsberger
Ruth Herbst
Original Assignee
Medigene Ag
Rainer Mueller
John Nieland
Josef Gabelsberger
Ruth Herbst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medigene Ag, Rainer Mueller, John Nieland, Josef Gabelsberger, Ruth Herbst filed Critical Medigene Ag
Priority to AU2002233220A priority Critical patent/AU2002233220A1/en
Priority to US10/433,091 priority patent/US20040101533A1/en
Publication of WO2002043757A2 publication Critical patent/WO2002043757A2/de
Publication of WO2002043757A3 publication Critical patent/WO2002043757A3/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Arzneimittel zur Vermeidung oder Behandlung von humanem Papillomavirus-Typ 18 (HPV-18)-spezifischen Tumor enthaltend mindestens ein Fusionsprotein aus mindestens einem L1-Protein und mindestens einem E-Protein eines oder mehrerer HPV-18 und gegebenenfalls geeignete Zusatz- und/oder Hilfsstoffe, dadurch gekennzeichnet, dass das Fusionsprotein ein L1Δc-E7x-y-Fusionsprotein ist, wobei x eine ganze Wahl von 1 bis einschließlich 3 und y eine ganze Zahl von 61 bis 64, insbesondere 62 bis 64, vor allem 62 oder 64 bedeutet.
PCT/EP2001/014038 2000-12-01 2001-11-30 Arzneimittel zur vermeidung oder behandlung von durch humanen papillomavirus-typ 18-hervorgerufenem tumor WO2002043757A2 (de)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2002233220A AU2002233220A1 (en) 2000-12-01 2001-11-30 Medicament for preventing or treating tumors caused by human papilloma virus type 18
US10/433,091 US20040101533A1 (en) 2000-12-01 2001-11-30 Medicament for preventing or treating tumors caused by human papilloma virus type 18

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE2000159630 DE10059630A1 (de) 2000-12-01 2000-12-01 Arzneimittel zur Vermeidung oder Behandlung von durch humanen Papillomavirus-Typ 18-hervorgerufenem Tumor
DE10059630.4 2000-12-01

Publications (2)

Publication Number Publication Date
WO2002043757A2 WO2002043757A2 (de) 2002-06-06
WO2002043757A3 true WO2002043757A3 (de) 2002-10-17

Family

ID=7665349

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/014038 WO2002043757A2 (de) 2000-12-01 2001-11-30 Arzneimittel zur vermeidung oder behandlung von durch humanen papillomavirus-typ 18-hervorgerufenem tumor

Country Status (4)

Country Link
US (1) US20040101533A1 (de)
AU (1) AU2002233220A1 (de)
DE (1) DE10059630A1 (de)
WO (1) WO2002043757A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4474264B2 (ja) 2004-08-20 2010-06-02 生寶生物科技股▲ふん▼有限公司 子宮頸癌抑制の融合蛋白
ATE476528T1 (de) 2004-12-08 2010-08-15 Gen Probe Inc Nukleinsäuredetektion aus verschiedenen typen des humanen papillomavirus
US9364529B2 (en) 2007-04-29 2016-06-14 Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Truncated L1 protein of human papillomavirus type 18
EP2154147B1 (de) 2007-04-29 2015-10-07 Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Gekürztes l1-protein des humanen papillomavirus 16
US20130171128A1 (en) * 2010-03-02 2013-07-04 Amgen Inc. Reducing viscosity of pharmaceutical formulations
EP2542700A4 (de) * 2010-03-04 2013-09-11 Purdue Research Foundation Integriertes assay mit kombination aus flusszytometrie und multiplexierter hpv-genotypen-identifikation
US9737250B2 (en) * 2013-03-15 2017-08-22 Dexcom, Inc. Membrane for continuous analyte sensors
WO2016006873A1 (ko) * 2014-07-09 2016-01-14 연세대학교 산학협력단 인유두종바이러스 펩타이드의 자궁경부암 진단 및 치료 용도
KR101680567B1 (ko) 2014-07-09 2016-11-29 연세대학교 산학협력단 인유두종바이러스 펩타이드의 자궁경부암 진단 및 치료 용도
CN114127295B (zh) * 2019-07-19 2024-05-14 神州细胞工程有限公司 嵌合的人乳头瘤病毒16型l1蛋白
EP4100051A2 (de) * 2020-02-07 2022-12-14 ISA Pharmaceuticals B.V. Behandlung von hpv-assoziierten erkrankungen

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999018220A1 (en) * 1997-10-06 1999-04-15 Loyola University Of Chicago Papilloma virus capsomere vaccine formulations and methods of use
DE19812941A1 (de) * 1998-03-24 1999-10-07 Medigene Ag Arzneimittel zur Vermeidung oder Behandlung von Papillomavirusspezifischem Tumor

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5004687A (en) * 1985-05-21 1991-04-02 University Of Georgia Research Foundation, Inc. Insect virus vector with broadened host range
US5820870A (en) * 1995-03-22 1998-10-13 Merck & Co., Inc. Recombinant human papillomavirus type 18 vaccine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999018220A1 (en) * 1997-10-06 1999-04-15 Loyola University Of Chicago Papilloma virus capsomere vaccine formulations and methods of use
DE19812941A1 (de) * 1998-03-24 1999-10-07 Medigene Ag Arzneimittel zur Vermeidung oder Behandlung von Papillomavirusspezifischem Tumor

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE SWISSPROT [online] SWISS INSTITUTE OF BIOINFORMATICS; 1 April 1990 (1990-04-01), "VE7_HPV18", XP002200690, retrieved from WWW.EBI.AC.UK Database accession no. P06788 *
DATABASE SWISSPROT [online] SWISS INSTITUTE OF BIOINFORMATICS; 21 July 1986 (1986-07-21), "VE7_HPV16", XP002200689, retrieved from WWW.EBI.AC.UK Database accession no. P03129 *
MÜLLER M ET AL.: "CHIMERIC PAPILLOMAVIRUS-LIKE PARTICLES", VIROLOGY, vol. 234, 1997, pages 93 - 111, XP002199960 *

Also Published As

Publication number Publication date
US20040101533A1 (en) 2004-05-27
WO2002043757A2 (de) 2002-06-06
DE10059630A1 (de) 2002-06-06
AU2002233220A1 (en) 2002-06-11

Similar Documents

Publication Publication Date Title
MXPA02012443A (es) Profarmaco en 3'' de 2'-desoxi-beta-l-nucleosidos.
BG100974A (en) Vaccines against papillomavirus
EA200201263A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ ИНФЕКЦИЙ, ВЫЗЫВАЕМЫХ ВИРУСОМ ГЕПАТИТА ДЕЛЬТА, С ИСПОЛЬЗОВАНИЕМ β-L-2'-ДЕЗОКСИНУКЛЕОЗИДОВ
YU68002A (sh) Modifikovani faktor viii
TW200730537A (en) Methods and compositions for treating hepatitis C virus
MXPA03007590A (es) Composiciones y metodos para mejorar suministro de droga a traves de y dentro de tejidos oculares.
WO2001089457A3 (en) Thrombopoietin mimetics
WO2001024816A3 (en) Compositions and methods relating to the inhibition of casomorphin and gluteomorphin
WO2002049413A3 (en) Thrombopoietin mimetics
WO2003000200A3 (en) β-2'-OR 3'-HALONUCLEOSIDES
WO2002043757A3 (de) Arzneimittel zur vermeidung oder behandlung von durch humanen papillomavirus-typ 18-hervorgerufenem tumor
MY118526A (en) Method for improving the pharmacokinetics of tipranavir
AU2002241736A1 (en) Method for preventing or treating pain by administering an endothelin antagonist
ATE226436T1 (de) Neue verwendung von dexmedetomidin
WO2001076638A3 (en) Compositions for drug delivery
BG105197A (en) Polymorph form of a medicament
MXPA03003741A (es) Metodos y composiciones para el tratamiento de enfermedades oftalmicas.
RS50148B (sr) Upotreba docetaksela za lečenje hepatoćelijskog karcinoma
ZA991029B (en) Composition and methods for treatment of hiv infections.
BR0207066A (pt) Derivados do 2h-1-benzopirano - processos para sua preparação e composições farmacêuticas a partir deles
EP0995430A3 (de) Verwendung von Wirkstoffen, gewählt aus der Gruppe der 1,2-Diacylglycerole, zur Stärkung der Barrierefunktion der Haut
YU45103A (sh) Upotreba sarp/1 za lečenje i prevenciju skleroderme
WO2003059387A3 (en) Combination comprising anti-cd52 antibodies and other therapeutic agents for treatment for multiple sclerosis
WO2002024727A3 (en) New inhibitors of iapp fibril formation and uses thereof
NZ514691A (en) Method to type prion proteins

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 10433091

Country of ref document: US

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP